6533b823fe1ef96bd127ec26

RESEARCH PRODUCT

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

Philippe D’athisAnca-maria MihaiCaroline LabordeValentine NussJérémie VovellePierre JouannyAlain PutotPatrick ManckoundiaJérémy Barben

subject

medicine.medical_specialtymultimorbidityHealth Toxicology and MutagenesisFrail ElderlyPopulationlcsh:MedicineunderuseDiseasefrailty030204 cardiovascular system & hematologyoveruseelderlyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMedical history030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'educationplatelet aggregation inhibitorsGeriatric AssessmentAgedAged 80 and overeducation.field_of_studyMini–Mental State Examinationmedicine.diagnostic_test[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologylcsh:RPublic Health Environmental and Occupational HealthOdds ratiocomprehensive geriatric assessmentConfidence intervalCross-Sectional StudiesagePlatelet aggregation inhibitorFemaleantiplatelet agentsbusiness

description

Platelet aggregation inhibitors (PAI) have widely proven their efficiency for the prevention of ischemic cardiovascular events. We aimed to describe PAI prescription in an elderly multimorbid population and to determine the factors that influence their prescription, including the impact of age, comorbidities and frailty, evaluated through a comprehensive geriatric assessment. This cross-sectional study included all patients admitted to the acute geriatric department of a university hospital from November 2016 to January 2017. We included 304 consecutive hospitalized patients aged 88.7 &plusmn

10.3390/ijerph17124541http://dx.doi.org/10.3390/ijerph17124541